• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.

作者信息

De Marchi S, Falleti E, Giacomello R, Stel G, Cecchin E, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E

机构信息

Department of Internal Medicine, University of Udine Medical School, Italy.

出版信息

J Am Soc Nephrol. 1996 Aug;7(8):1169-77. doi: 10.1681/ASN.V781169.

DOI:10.1681/ASN.V781169
PMID:8866409
Abstract

Vascular access dysfunction is an important cause of morbidity for dialysis patients and a major contributor to hemodialysis cost. Thrombosis is a leading cause of vascular access failure, and usually results from stenotic lesions in the venous outflow system. This study was designed to explore the impact of serum levels of various risk factors for thrombosis and accelerated fibrointimal hyperplasia on progressive stenosis, and the subsequent thrombosis of hemodialysis fistula. A cross-sectional and 2-yr prospective pilot study was performed in 30 nondiabetic hemodialysis patients with primary arteriovenous fistula. Venous dialysis pressure, urea recirculation, color Doppler sonography, and angiography were used to monitor vascular access patency. Eleven patients (37%) developed a progressive stenosis in the venous circuit, which was complicated by thrombosis in three patients. Compared with the patients without fistula dysfunction, these patients had higher serum levels of monocyte chemoattractant protein-1 and interleukin-6, two cytokines that regulate the proliferation of vascular smooth muscle cells, which is the key mechanism in the pathogenesis of fistula stenosis. In addition, they had hyperinsulinemia, hyperlipidemia, and increased plasma levels of two hemostasis-derived risk factors for thrombosis: plasminogen activator inhibitor type 1 and factor VII. Monocyte chemoattractant protein-1, interleukin-6, plasminogen activator inhibitor type 1, factor VII, triglycerides, and the ratios for cholesterol/HDL-cholesterol, apolipoprotein (apo) A-I/ apo C-III, apo A-I/apo B, and glucose/insulin were independent predictors of fistula dysfunction. This study demonstrates the influece of cytokines, hemostasis-derived vascular risk factor, hyperinsullnemia, and abnormallties of lipids and apolipoproteins on primary fistula survival. The assessment of these factors might be useful for the identification of the patients at risk of fistula stenosis and thrombosis.

摘要

相似文献

1
Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.
J Am Soc Nephrol. 1996 Aug;7(8):1169-77. doi: 10.1681/ASN.V781169.
2
Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients.促红细胞生成素治疗对血液透析患者内瘘狭窄及血小板衍生生长因子和单核细胞趋化蛋白-1血浆浓度的长期影响。
J Am Soc Nephrol. 1997 Jul;8(7):1147-56. doi: 10.1681/ASN.V871147.
3
Serum LDL levels are a major prognostic factor for arteriovenous fistula thrombosis (AVFT) in hemodialysis patients.血清低密度脂蛋白水平是血液透析患者动静脉内瘘血栓形成(AVFT)的主要预后因素。
J Vasc Access. 2007 Apr-Jun;8(2):109-14.
4
Arteriovenous fistula thrombosis in patients on regular hemodialysis: a report of 171 patients.规律血液透析患者动静脉内瘘血栓形成:171例患者的报告
Arch Iran Med. 2006 Jan;9(1):26-32.
5
A Retrospective Case-Control Study on Late Failure of Arteriovenous Fistula in Hemodialysis Patients and Prediction of Risk Factors.回顾性病例对照研究:血液透析患者动静脉瘘晚期失功及危险因素预测。
Comput Math Methods Med. 2022 Mar 8;2022:8110289. doi: 10.1155/2022/8110289. eCollection 2022.
6
Subjective Global Assessment-Dialysis Malnutrition Score and arteriovenous fistula outcome: A comparison with Charlson Comorbidity Index.主观全面评定-透析营养不良评分与动静脉内瘘结局:与Charlson合并症指数的比较
J Vasc Access. 2019 Jan;20(1):70-78. doi: 10.1177/1129729818779550. Epub 2018 Jun 7.
7
A novel factor for primary arteriovenous fistula failure: hyperinsulinism.原发性动静脉内瘘失败的一个新因素:高胰岛素血症。
Ren Fail. 2016 Sep;38(8):1206-9. doi: 10.1080/0886022X.2016.1209061. Epub 2016 Jul 27.
8
Relationship of arteriovenous fistula stenosis and thrombosis with the platelet-lymphocyte ratio in hemodialysis patients.血液透析患者动静脉内瘘狭窄和血栓形成与血小板-淋巴细胞比值的关系。
J Vasc Access. 2020 Sep;21(5):630-635. doi: 10.1177/1129729819894113. Epub 2019 Dec 30.
9
Association of serum lipid profile and arteriovenous fistula thrombosis in maintenance hemodialysis patients.维持性血液透析患者血清脂质谱与动静脉内瘘血栓形成的相关性
Blood Purif. 2008;26(4):322-32. doi: 10.1159/000132388. Epub 2008 May 19.
10
Cross-talk between inflammation,coagulation/fibrinolysis and vascular access in hemodialysis patients.血液透析患者炎症、凝血/纤维蛋白溶解与血管通路之间的相互作用
J Vasc Access. 2008 Oct-Dec;9(4):248-53.

引用本文的文献

1
From Uremic Toxins to Hemodialysis Access Failure: IL-8 and MCP-1 Chemokines as a Link Between Endothelial Activation and AV Access Complications.从尿毒症毒素到血液透析通路失败:白细胞介素-8和单核细胞趋化蛋白-1趋化因子作为内皮激活与动静脉通路并发症之间的联系
Toxins (Basel). 2025 Aug 31;17(9):434. doi: 10.3390/toxins17090434.
2
Dual outflow upper arm arteriovenous fistula: An effective technique to prevent cephalic arch stenosis.双流出上臂动静脉瘘:预防头臂弓狭窄的有效技术。
Medicine (Baltimore). 2023 Dec 1;102(48):e36419. doi: 10.1097/MD.0000000000036419.
3
Contemporary review of management techniques for cephalic arch stenosis in hemodialysis.
当代综述:血液透析患者头臂动脉狭窄的治疗技术。
Ren Fail. 2023 Dec;45(1):2176166. doi: 10.1080/0886022X.2023.2176166.
4
Oxidative stress: An essential factor in the process of arteriovenous fistula failure.氧化应激:动静脉内瘘失败过程中的一个关键因素。
Front Cardiovasc Med. 2022 Aug 11;9:984472. doi: 10.3389/fcvm.2022.984472. eCollection 2022.
5
Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia.血管通路在儿童纯合子家族性高胆固醇血症患者行血脂吸附治疗中的应用。
BMC Pediatr. 2022 Mar 12;22(1):131. doi: 10.1186/s12887-022-03192-7.
6
The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis.促红细胞生成素刺激剂与血液透析患者动静脉瘘功能障碍风险增加的关联。一项回顾性分析。
BMC Nephrol. 2021 Jan 18;22(1):30. doi: 10.1186/s12882-020-02209-6.
7
Experimental murine arteriovenous fistula model to study restenosis after transluminal angioplasty.实验性鼠动静脉瘘模型用于研究经腔内血管成形术后再狭窄。
Lab Anim (NY). 2020 Nov;49(11):320-334. doi: 10.1038/s41684-020-00659-x. Epub 2020 Oct 20.
8
Mean Platelet Volume Predicts Vascular Access Events in Hemodialysis Patients.平均血小板体积可预测血液透析患者的血管通路事件。
J Clin Med. 2019 May 4;8(5):608. doi: 10.3390/jcm8050608.
9
Antiplatelet agents maintain arteriovenous fistula and graft function in patients receiving hemodialysis: A nationwide case-control study.抗血小板药物可维持接受血液透析患者动静脉瘘和移植物功能:一项全国性病例对照研究。
PLoS One. 2018 Oct 18;13(10):e0206011. doi: 10.1371/journal.pone.0206011. eCollection 2018.
10
Significant association of anti-platelet factor 4/heparin antibody with cardiovascular disease in hemodialysis patients: a longitudinal 7-year study.抗血小板因子4/肝素抗体与血液透析患者心血管疾病的显著关联:一项为期7年的纵向研究。
Int Urol Nephrol. 2018 Dec;50(12):2289-2297. doi: 10.1007/s11255-018-2002-y. Epub 2018 Oct 15.